中国医学创新2016，Vol.13Issue(28)：7-10,4.DOI:10.3969/j.issn.1674-4985.2016.28.002
雷珠单抗联合黄斑区格栅样光凝治疗视网膜分支静脉阻塞的临床疗效及安全性
Clinical Effect and Safety of Ranibizumab Treatment Combined with Macular Grid Photocoagulation in Patitents with Branch Retinal Vein Occlusion
摘要
Abstract
Objective:To summarize the application effect and adverse reaction conditions of ranibizumab treatment combined with macular grid photocoagulation in branch retinal vein occlusion(BRVO) secondary yellow cystic edema(CME) patients.Method:From July 2014 to May 2015,60 cases of BRVO secondary CME in our hospital were selected as the research objects,they were randomly divided into three groups,each group had 20 cases.Group A was given pure GLP treatment,group B was given simple monoclonal ranibizumab antibody injection treatment,group C was given monoclonal ranibizumab antibody combined with macular grid photocoagulation,the best corrected visual acuity(BCVA), macular central thickness(CMT),treatment effect and adverse reaction rate were compared among three groups before and after treatment.Result:There were no significant differences in CMT and BCVA among three groups before treatment(P>0.05),BCVA showed an increasing trend and CMT showed a decreasing trend in three groups after treatment,followed up 1,3 and 6 months,the BCVA of group C was higher than group A and B,the CMT was lower than group A and B,the differences were statistically significant(P<0.05),the differences of CMT and BCVA in group A and B were not statistically significant (P>0.05).After 6 months followed-up,the total effective rate of group C were significantly higher than that of the group A and group B,the differences were statistically significant(P<0.05),but there was no statistically significant (P>0.05).There were no significant differences in the incidence of adverse reactions among three groups(P>0.05). Conclusion:Ranibizumab treatment combine with macular grid photocoagulation can effectively improve the therapeutic effect of BRVO secondary CME, does not increase the incidence of adverse reactions.关键词
雷珠单抗/黄斑区格栅样光凝/视网膜分支静脉阻塞/黄斑囊样水肿Key words
Ranibizumab/Macular grid photocoagulation/Branch retinal vein occlusion/Yellow cystic edema引用本文复制引用
严槟,尹小芳,叶祖科,卢彦,洪剑威..雷珠单抗联合黄斑区格栅样光凝治疗视网膜分支静脉阻塞的临床疗效及安全性[J].中国医学创新,2016,13(28):7-10,4.基金项目
广东省佛山市科技计划项目 （）
